JP2007530551A5 - - Google Patents

Download PDF

Info

Publication number
JP2007530551A5
JP2007530551A5 JP2007505055A JP2007505055A JP2007530551A5 JP 2007530551 A5 JP2007530551 A5 JP 2007530551A5 JP 2007505055 A JP2007505055 A JP 2007505055A JP 2007505055 A JP2007505055 A JP 2007505055A JP 2007530551 A5 JP2007530551 A5 JP 2007530551A5
Authority
JP
Japan
Prior art keywords
seq
monoclonal antibody
nos
myostatin
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007505055A
Other languages
English (en)
Japanese (ja)
Other versions
JP4695133B2 (ja
JP2007530551A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/009307 external-priority patent/WO2005094446A2/en
Publication of JP2007530551A publication Critical patent/JP2007530551A/ja
Publication of JP2007530551A5 publication Critical patent/JP2007530551A5/ja
Application granted granted Critical
Publication of JP4695133B2 publication Critical patent/JP4695133B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007505055A 2004-03-23 2005-03-17 抗ミオスタチン抗体 Expired - Fee Related JP4695133B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55545604P 2004-03-23 2004-03-23
US60/555,456 2004-03-23
US55962104P 2004-04-05 2004-04-05
US60/559,621 2004-04-05
PCT/US2005/009307 WO2005094446A2 (en) 2004-03-23 2005-03-17 Anti-myostatin antibodies

Publications (3)

Publication Number Publication Date
JP2007530551A JP2007530551A (ja) 2007-11-01
JP2007530551A5 true JP2007530551A5 (cg-RX-API-DMAC7.html) 2009-02-12
JP4695133B2 JP4695133B2 (ja) 2011-06-08

Family

ID=35064367

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007505055A Expired - Fee Related JP4695133B2 (ja) 2004-03-23 2005-03-17 抗ミオスタチン抗体

Country Status (14)

Country Link
US (1) US20070178095A1 (cg-RX-API-DMAC7.html)
EP (1) EP1733041B1 (cg-RX-API-DMAC7.html)
JP (1) JP4695133B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060133049A (cg-RX-API-DMAC7.html)
AT (1) ATE557042T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005227896B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0508716A (cg-RX-API-DMAC7.html)
CA (1) CA2558805C (cg-RX-API-DMAC7.html)
EA (1) EA014112B1 (cg-RX-API-DMAC7.html)
ES (1) ES2384176T3 (cg-RX-API-DMAC7.html)
IL (1) IL177956A (cg-RX-API-DMAC7.html)
MX (1) MXPA06010929A (cg-RX-API-DMAC7.html)
NO (1) NO20064788L (cg-RX-API-DMAC7.html)
WO (1) WO2005094446A2 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003301195B2 (en) 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
TW200724548A (en) * 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
KR101135220B1 (ko) * 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US20070149458A1 (en) * 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
HRP20130320T1 (en) * 2006-09-05 2013-05-31 Eli Lilly And Company Anti-myostatin antibodies
AU2008285289A1 (en) 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
HUP0800448A2 (en) * 2008-07-21 2011-02-28 Pecsi Tudomanyegyetem Diagnosis of systemic diseases
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
FR2943249B1 (fr) * 2009-03-18 2011-08-12 Genethon Utilisation de la decorine pour augmenter la masse musculaire
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
SMT201800092T1 (it) 2011-11-14 2018-03-08 Regeneron Pharma Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
FR2982860B1 (fr) 2011-11-18 2015-07-10 Ass Fr Contre Les Myopathies Utilisation de la fibromoduline et du lumican pour augmenter la masse musculaire
BR112014017814A8 (pt) * 2012-01-20 2017-07-11 Genzyme Corp Anticorpos anti-cxcr3
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
MY177331A (en) * 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
EP4678239A3 (en) 2012-08-01 2026-04-08 Ikaika Therapeutics, Inc. Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスFcγRII特異的Fc抗体
RS58801B1 (sr) 2012-09-13 2019-07-31 Bristol Myers Squibb Co Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
EP2983694B1 (en) 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
EP3881859B1 (en) * 2013-06-11 2024-03-06 President and Fellows of Harvard College Compositions for increasing neurogenesis and angiogenesis
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素a之抗體及其用途
TW201622743A (zh) * 2014-03-19 2016-07-01 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 免疫原醣肽、包含該醣肽之組合物及其用途
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
EP3394098A4 (en) * 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
IL293766B2 (en) 2016-01-06 2023-08-01 Harvard College Treatment with gdf11 prevents weight gain, improves glucose loading and reduces hepatosteatosis
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
TWI760396B (zh) 2016-06-17 2022-04-11 日商中外製藥股份有限公司 抗肌抑素抗體及使用方法
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
HRP20230308T1 (hr) * 2017-01-06 2023-05-12 Scholar Rock, Inc. Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina
IL276921B2 (en) 2018-03-01 2025-12-01 Regeneron Pharma Methods for altering body composition
SMT202500283T1 (it) 2018-04-06 2025-09-12 Regeneron Pharma Un anticorpo agonista del recettore della leptina da utilizzare per aumentare la massa ossea in un soggetto affetto da disfunzione metabolica o ipoleptinemia
CN113195532B (zh) 2018-12-18 2025-04-11 瑞泽恩制药公司 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
AU2019406214A1 (en) 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
JP2025532651A (ja) 2022-09-21 2025-10-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 肥満、糖尿病および肝機能障害を処置する方法
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂
US20260199503A1 (en) 2025-01-10 2026-07-16 Regeneron Pharmaceuticals, Inc. Glp1r agonist-tethered gdf8 antibody conjugates and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20030074680A1 (en) * 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
CA2157577C (en) * 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
ES2233974T3 (es) * 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
ES2330062T3 (es) * 1998-05-06 2009-12-03 Metamorphix, Inc. Procedimientos para tratar la diabetes por inhibicion de gdf-8.
US6537781B1 (en) * 1999-08-10 2003-03-25 Idexx Laboratories, Inc. Methods and compositions concerning canine interleukin 5
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof

Similar Documents

Publication Publication Date Title
US20210024635A1 (en) Anti-wt1/hla-specific antibodies
JP5782479B2 (ja) PEG化AβFAB
CN104774266B (zh) 白介素-13结合蛋白
JP5903382B2 (ja) 治療用dll4結合タンパク質
JP2023027258A (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
CA2800581C (en) Antibodies to human gdf8
AU2005227896B2 (en) Anti-myostatin antibodies
JP2022037133A (ja) 改良された血清アルブミン結合剤
JP2020120684A (ja) Gタンパク質共役受容体を標的化する抗体および使用の方法
JP6513657B2 (ja) Il−17a結合剤およびその用途
JP7257971B6 (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
JP7304320B2 (ja) 抗Pre-S1 HBV抗体
JP2012504955A5 (cg-RX-API-DMAC7.html)
JP2019518459A (ja) Lag−3抗体、その抗原結合フラグメント、およびそれらの医薬的用途
JP2022513043A5 (cg-RX-API-DMAC7.html)
JP6949012B2 (ja) B型肝炎表面抗原に対する抗体及びその使用
KR20120135419A (ko) 치료학적 dll4 결합 단백질
JP2010535509A (ja) ヒト神経成長因子に対する高親和性ヒト抗体
WO2015137843A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
JP2019507580A5 (cg-RX-API-DMAC7.html)
JP2019505166A5 (cg-RX-API-DMAC7.html)
JP2021512159A5 (cg-RX-API-DMAC7.html)
US20240092875A1 (en) Sars-cov-2 antibodies for treatment and prevention of covid-19
JP2015525075A (ja) Ca215に対するヒト化抗体
JP2025508603A (ja) ネコ抗体ライブラリー